The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome-Reference-Cited by-同舟云学术

The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome

Published:2019-03-01 Issue:2 Volume:2 Page:134-142
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Drucker Daniel J.¹^ORCID

Affiliation:

1. From the Department of Medicine, the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario M5G 1X5, Canada

Funder

Institute of Nutrition, Metabolism and Diabetes

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.9b00016

Reference53 articles.

1. Glucagon Physiology and Pathophysiology

2. Exon duplication and divergence in the human preproglucagon gene

3. Hamster preproglucagon contains the sequence of glucagon and two related peptides

4. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon.

5. Pre-Proglucagon Messenger Ribonucleic Acid: Nucleotide and Encoded Amino Acid Sequences of the Rat Pancreatic Complementary Deoxyribonucleic Acid*

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment;Bioactive Materials;2024-02

2. Principles of management of patients with short bowel syndrome;Meditsinskiy sovet = Medical Council;2024-01-19

3. Non‐insulin Parenteral Therapies;Textbook of Diabetes;2024-01-12

4. ESPEN guideline on chronic intestinal failure in adults – Update 2023;Clinical Nutrition;2023-10

5. Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome;Nutrients;2023-09-29